M&A Deal Summary

United Therapeutics Acquires Miromatrix

On October 30, 2023, United Therapeutics acquired life science company Miromatrix for 91M USD

Acquisition Highlights
  • This is United Therapeutics’ 2nd transaction in the Life Science sector.
  • This is United Therapeutics’ 3rd largest (disclosed) transaction.
  • This is United Therapeutics’ 4th transaction in the United States.
  • This is United Therapeutics’ 1st transaction in Minnesota.

M&A Deal Summary
Date 2023-10-30
Target Miromatrix
Sector Life Science
Buyer(s) United Therapeutics
Deal Type Add-on Acquisition
Deal Value 91M USD
Advisor(s) Piper Sandler & Co.
Craig-Hallum (Financial)
Faegre Drinker Biddle & Reath (Legal)

Target

Miromatrix

Eden Prairie, Minnesota, United States
Miromatrix is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. Miromatrix Medical has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. Miromatrix was founded in 2009 and is headquartered in Eden Prairie, Minnesota.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

United Therapeutics

Silver Spring, Maryland, United States
Category Company
Founded 1996
Sector Medical Products
Employees950
Revenue 2.3B USD (2023)
DESCRIPTION

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics was founded in 1996 and is based in Silver Spring, Maryland.

DEAL STATS #
Overall 4 of 4
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 3 of 3
State (Minnesota) 1 of 1
Country (United States) 4 of 4
Year (2023) 1 of 1
Size (of disclosed) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-12-28 Rare Pediatric Disease Priority Review Voucher

United States

Rare Pediatric Disease Priority Review Voucher (PPRV) is a provider of biotechnology services.

Buy $105M
Mergr

Product

Company

Legal